Skip to main content


Psych Congress 2020 presenter Timothy Wilens, MD, discusses the ways in which early treatment can improve outcomes in patients with attention-deficit/hyperactivity disorder (ADHD). 
AR19, an investigational stimulant for attention-deficit/hyperactivity disorder (ADHD), improved symptoms in adults with ADHD in a Phase 3 trial, according to a poster presented at Psych Congress 2020.
Attention-deficit/hyperactive disorder (ADHD) and narcolepsy may share genetic links, according to an analysis of polygenic risk scores published online in the journal Translational Psychiatry.
Treatment with a central stimulant may reduce the risk of suicide attempt and nonsuicidal self-injury in adults with bipolar disorder and attention-deficit/hyperactivity disorder. 
Attentional behaviors observed in babies at 12 months of age appear to predict behaviors related to attention-deficit/hyperactivity disorder (ADHD) at 4.5 years of age.
Back to Top